Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie
September 04 2019 - 7:00AM
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that
they have entered into an immuno-oncology clinical research
collaboration with AbbVie, a global, research-based
biopharmaceutical company. The purpose of the collaboration
is to conduct a clinical study evaluating whether combinations of
an OX40 agonist (ABBV-368), a TLR-9 agonist (tilsotolimod),
chemotherapy (nab-paclitaxel) and/or an anti-programmed cell death
1 (PD-1) antagonist (ABBV-181) stimulate the immune system
resulting in anti-tumor responses.
This Phase 1b, multi-center, open-label study is designed to
determine the safety, tolerability, pharmacokinetics and
preliminary efficacy of combinations of ABBV-368 plus tilsotolimod
in subjects with recurrent or metastatic head and neck squamous
cell carcinoma (HNSCC).
The study will test three separate treatment arms:
- ABBV-368 plus tilsotolimod;
- ABBV-368 plus tilsotolimod and nab-paclitaxel; and
- ABBV-368 plus tilsotolimod, nab-paclitaxel and ABBV-181.
Under the terms of the agreement, Idera will provide clinical
trial supply of tilsotolimod to AbbVie and AbbVie will be
responsible for conduct of the study.
“We are excited to be entering into this additional clinical
collaboration, which continues to advance our strategy of exploring
the possibilities to further improve patient outcomes harnessing
the immune system against difficult to treat cancers, which
historically have not generated significant objective response
rates through checkpoint inhibition alone,” stated Elizabeth A.
Tarka, M.D., F.A.C.C., Idera’s Chief Medical Officer. “We
look forward to working together with AbbVie to advance our
understanding of the combination effect of ABBV-368 and
tilsotolimod for these patients.”
About Idera PharmaceuticalsHarnessing the
approach of the earliest researchers in immunotherapy and the
Company’s vast experience in developing proprietary immunology
platforms, Idera’s lead development program is focused on priming
the immune system to play a more powerful role in fighting cancer,
ultimately increasing the number of people who can benefit from
immunotherapy. Idera also continues to focus on the acquisition,
development and ultimate commercialization of drug candidates for
both oncology and rare disease indications characterized by small,
well-defined patient populations with serious unmet needs. To learn
more about Idera, visit www.iderapharma.com.
Idera Forward Looking Statements This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. All
statements, other than statements of historical fact, included or
incorporated in this press release, including statements regarding
the Company's strategy, future operations, collaborations,
intellectual property, cash resources, financial position, future
revenues, projected costs, prospects, clinical trials, plans, and
objectives of management, are forward-looking statements. The words
"believes," "anticipates," "estimates," "plans," "expects,"
"intends," "may," "could," "should," "potential," "likely,"
"projects," "continue," "will," and "would" and similar expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.
Idera cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking
statements and you should not place undue reliance on the Company's
forward-looking statements. There are a number of important factors
that could cause Idera's actual results to differ materially from
those indicated or implied by its forward-looking statements.
Factors that may cause such a difference include: whether the
Company’s cash resources will be sufficient to fund the Company’s
continuing operations and the further development of the Company’s
programs for the period anticipated; whether interim results from a
clinical trial, such as the preliminary results reported in this
release, will be predictive of the final results of the trial;
whether results obtained in preclinical studies and clinical trials
such as the results described in this release will be indicative of
the results that will be generated in future clinical trials,
including in clinical trials in different disease indications;
whether products based on Idera's technology will advance into or
through the clinical trial process when anticipated or at all or
warrant submission for regulatory approval; whether such products
will receive approval from the U.S. Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the Company's collaborations will be
successful; and such other important factors as are set forth under
the caption "Risk factors" in the Company’s Annual Report filed on
Form 10-K for the period ended December 31, 2018. While Idera may
elect to do so at some point in the future, the Company does not
assume any obligation to update any forward-looking statements and
it disclaims any intention or obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.Idera Pharmaceuticals
Contact:Robert A. Doody, Jr.SVP, Investor
Relations & CommunicationsPhone (484)
348-1677rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024